HSBC/CALL/MODERNA/180/0.1/15.01.25 | Market Closed - Boerse Frankfurt Warrants 01:05:22 29/06/2024 am IST | ||
| 0.54 EUR | -8.47% |
|
| 1 month | -69.32% | ||
| 3 months | +1.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.54 | -8.47% |
| 27/24/27 | 0.59 | -10.61% |
| 26/24/26 | 0.66 | -35.92% |
| 25/24/25 | 1.03 | +0.98% |
| 24/24/24 | 1.02 | +5.15% |
Real-time Boerse Frankfurt Warrants
Last update June 29, 2024 at 01:05 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807G |
| ISIN | DE000HG807G1 |
| Date issued | 02/02/2023 |
| Strike | 180 $ |
| Maturity | 15/01/2025 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 5.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.35 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.02 € |
| Spread % | 3.57% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
